KROS (Keros Therapeutics) FCF Yield % : -34.99 (As of Mar. 13, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Keros Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Keros Therapeutics's Trailing 12-Month Free Cash Flow is $-162.80 Mil, and Market Cap is $465.25 Mil. Therefore, Keros Therapeutics's FCF Yield % for today is -34.99%.

The historical rank and industry rank for Keros Therapeutics's FCF Yield % or its related term are showing as below:

KROS' s FCF Yield % Range Over the Past 10 Years
Min: -39.09 Med: -5.99 Max: -2.12
Current: -34.99

During the past 7 years, the highest FCF Yield % of Keros Therapeutics was -2.12%. The lowest was -39.09%. And the median was -5.99%.

KROS's FCF Yield % is ranked worse than
68.89% of 1498 companies
in the Biotechnology industry
Industry Median: -14.51 vs KROS: -34.99

Keros Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was -1,521.93%.

Keros Therapeutics FCF Yield % Historical Data

The historical data trend for Keros Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keros Therapeutics FCF Yield % Chart

Keros Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Yield %

Get a 7-Day Free Trial

-2.27

-4.50

-5.39

-10.03

-25.36

Keros Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Yield %	Get a 7-Day Free Trial															-8.21	-7.62	-9.71	-5.42	-28.85

Competitive Comparison of Keros Therapeutics's FCF Yield %

For the Biotechnology subindustry, Keros Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Keros Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keros Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Keros Therapeutics's FCF Yield % falls into.

Keros Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Keros Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-162.8	/	641.98565
	=	-25.36%

Keros Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-46.297	*	4	/	641.98565
	=	-28.85%

Keros Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Keros Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Keros Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Keros Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keros Therapeutics Inc (NAS:KROS) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1050 Waltham Street, Suite 302, Lexington, MA, USA, 02421

Website

https://www.kerostx.com

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Executives

Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Keith Regnante	officer: Chief Financial Officer	733 CONCORD AVENUE, CAMBRIDGE MA 02138
Alpna Seth	director	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Jennifer Lachey	officer: Chief Scientific Officer	C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Christopher Rovaldi	officer: Chief Operating Officer	C/O ACCELERON PHARMA INC., 128 SIDNEY ST., CAMBRIDGE MA 02139
Julius Knowles	director	C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Simon Peter Cooper	officer: Chief Medical Officer	C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVE., BUILDING E, SUITE 120, LEXINGTON MA 02421
Claudia Ordonez	officer: Chief Medical Officer	C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Mary Ann Gray	director	201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
Pontifax Management 4 G.p. (2015) Ltd.	10 percent owner	14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Ran Nussbaum	director, 10 percent owner	C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Tomer Kariv	director, 10 percent owner	C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Jasbir Seehra	director, officer: Chief Executive Officer	C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM MA 02451
Alon Lazarus	director, 10 percent owner	C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421